We are live on ! Find out more
GANX icon

Gain Therapeutics

26 hedge funds and large institutions have $7.04M invested in Gain Therapeutics in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

208% more capital inflows, than outflows

Capital inflows: $2.03M | Capital outflows: $658K

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

43% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 7

42% more call options, than puts

Call options by funds: $85K | Put options by funds: $60K

8% more funds holding

Funds holding: 24 → 26 (+2)

1.58% more ownership

Funds ownership: 7.55% → 9.13% (+1.6%)

Holders
26
Holders Change
+2
Holders Change %
+8.33%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
10
Reduced
7
Closed
3
Calls
$85​K
Puts
$60​K
Net Calls
+$25​K
Net Calls Change
–

GANX Hedge Fund Activity: Q1 2024 in Review

26 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q1 2024, worth a combined $7.04M — up 40% from $5.05M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new GANX positions and 3 closed out — a net gain of 2 holders — while 10 added to existing stakes and 7 trimmed.

The largest buyer was Raymond James & Associates, adding an estimated $979K. The largest seller was Citadel Advisors, cutting an estimated $254K.

  • 26 institutional investors held Gain Therapeutics (GANX) as of Q1 2024, up from 24 in Q4 2023.
  • Funds reported $7.04M of Gain Therapeutics stock for Q1 2024, up 40% quarter-over-quarter.
  • 5 funds opened new Gain Therapeutics positions in Q1 2024 and 3 closed out, a net change of +2 holders.
  • The largest Gain Therapeutics buyer in Q1 2024 was Raymond James & Associates, an estimated $979K added.
  • The largest Gain Therapeutics seller in Q1 2024 was Citadel Advisors, an estimated $254K sold.

Based on aggregated 13F filings for Q1 2024.